Anti-Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD

Parambir S. Dulai, Corey A. Siegel, Laurent Peyrin-Biroulet*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

Inflammatory bowel disease (IBD) treatment has progressed significantly over the past decade with the advent of biologics. Anti-tumor necrosis factor (anti-TNF) agents are the most widely available biologics, but the optimal approach when using them remains unclear. In this review, we highlight the currently available evidence regarding the use of anti-TNF monotherapy versus combination therapy with an immunomodulator. We focus on those patients at greatest risk for adverse events and outline the clinical approach when considering the use of combination therapy. We review the available tools through which providers may efficiently communicate these data to patients in the clinical setting.

Original languageEnglish (US)
Pages (from-to)441-456
Number of pages16
JournalGastroenterology Clinics of North America
Volume43
Issue number3
DOIs
StatePublished - Sep 2014
Externally publishedYes

Keywords

  • Anti-TNF
  • Combination therapy
  • Immunomodulator
  • Monotherapy

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Anti-Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD'. Together they form a unique fingerprint.

Cite this